For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG is pleased to announce that the fall recipient of the Frances A. Shepherd Award is Dr. Assouline Division of Hematology McGill University, Jewish General Hospital Montreal, Quebec and the CCTG Hematologic Disease Site Chair
CCTG LY17 is a A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma. The trial is looking to determine the overall response rate (complete and partial response) to novel combination therapy in patients with relapsed and refractory aggressive B cell lymphoma. Dr. Kuruvilla and Dr. Crump stress the importance of this trial, collaboration within CCTG, and the overall benefit of cancer clinical trials. (NCT02436707)
IND229 Publication: A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2 - Positive Metastatic Breast Cancer
IND222 Publication: A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: A CCTG study.
Citations which reference published CCTG trials for MAC12, MA27 and MAC1
The following CCTG trials have been permanently closed.
Dr. O'Callaghan oversee the Gastrointestinal and Brain Site Committees as Senior Investigator. He is also a Professor in the Department of Public Health Sciences. His research interests are diverse and include clinical trials design and methodology and infectious disease epidemiology.
IND 221: Dose-ranging and cohort-expansion study of monalizumab(IPH2201) in advanced gynecologic malignancies
IND 208: A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
The CCTG ENC1 study, A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC#776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer, has been centrally activated and open to accrual.
